What is HC Wainwright’s Estimate for MBRX Q1 Earnings?

Moleculin Biotech, Inc. (NASDAQ:MBRX) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Moleculin Biotech in a research report issued on Tuesday, March 24th. HC Wainwright analyst S. Nik expects that the company will post earnings of ($1.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.60) EPS.

Several other research analysts have also issued reports on the company. Roth Mkm restated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Moleculin Biotech has an average rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock opened at $2.49 on Thursday. The firm has a fifty day moving average of $3.29 and a two-hundred day moving average of $6.91. The stock has a market capitalization of $5.08 million, a price-to-earnings ratio of -0.08 and a beta of 1.73. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $28.75.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.